🇺🇸 FDA

Intelligence Platform

Patents

Browse 67 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12390463

Dosage forms and regimens for amino acid compounds

Pliant Therapeutics, Inc. · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12370163

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12370181

Regimens of estrogen receptor antagonists

Olema Pharmaceuticals, Inc. · Granted Tue Jul 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12364683

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12343381

Dosage regimen for pegylated interferon

PHARMAESSENTIA CORPORATION · Granted Tue Jul 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12336980

Dosing regimen for a selective S1P1 receptor agonist

VANDA PHARMACEUTICALS INC. · Granted Tue Jun 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12303482

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12303481

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12295931

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12290566

Dosing regimens and related compositions and methods

Apellis Pharmaceuticals, Inc. · Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12263149

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12263148

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12213989

Use of maribavir in treatment regimens

Takeda Pharmaceutical Company Limited · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201596

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12194150

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12194079

Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

Protalix Ltd. · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12138247

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109196

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109185

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090140

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12029788

Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that i

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11998528

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11998529

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11986449

Levodopa dosing regimen

AMNEAL PHARMACEUTICALS LLC · Granted Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted